*仅供医学专业人士阅读参考

2024 ASCO乳腺癌领域有哪些新进展？

整理 |羊羊

2024年美国临床肿瘤学会（ASCO）年会将于美国时间5月31日至6月4日在芝加哥盛大召开。日前，ASCO官网公布了本次会议的摘要题目。医学界特此整理乳腺癌领域的口头摘要（Oral Abstract Session）和快速口头摘要（Rapid Oral Abstract Session）标题，供读者参考与学习。

HER2+乳腺癌：单抗类药物与ADC“争夺”天下

■摘要号：1007

Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD)

日本多中心、随机、非劣效性III期试验（JBCRG-M06/EMERALD）结果：曲妥珠单抗+帕妥珠单抗联合艾立布林或紫杉醇一线化疗治疗HER2+、局部晚期或转移性乳腺癌

讲者: Toshinari Yamashita, MD, PhD | Kanagawa Cancer Center

■摘要号：1008


Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.

随机II期研究PATRICIA 队列 C（SOLTI-1303）的主要结果：评价哌柏西利联合曲妥珠单抗和内分泌治疗用于经治HER2+和PAM50 luminal型乳腺癌

讲者: Eva Ciruelos, MD, PhD | Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre
■摘要号：1009


DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

DESTINY-Breast07：在既往未经治疗的HER2+ 转移性乳腺癌患者中进行T-DXd单药治疗和T-DXd+帕妥珠单抗联合治疗的剂量扩展中期分析

讲者: Fabrice Andre, MD, PhD | Gustave Roussy, Université Paris-Saclay

■摘要号：1020


ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC)

ACE-Breast-02：ARX788（一种新型抗HER2 ADC）与拉帕替尼联合卡培他滨治疗HER2+晚期乳腺癌的关键II/III期研究

讲者: 胡夕春教授 | 复旦大学附属肿瘤医院

HER2-乳腺癌：经典研究再更新

■摘要号：LBA1001

Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial

III期临床试验postMONARCH的主要结局：阿贝西利+氟维司群vs氟维司群单药治疗既往CDK4/6抑制剂联合内分泌治疗后进展的HR+、HER2-晚期乳腺癌

讲者: Kevin Kalinsky, MD, MS | Winship Cancer Institute of Emory University
■摘要号：LBA1002

Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL

随机II期Young-PEARL研究更新生存结局：哌柏西利+依西美坦联合GnRH激动剂vs卡培他滨治疗绝经前HR+/HER2-转移性乳腺癌

讲者: Yeon Hee Park, MD, PhD | Samsung Medical Center, Sungkyunkwan University
■摘要号：1003


First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses

III期随机试验INAVO120的额外分析：inavolisib/安慰剂+哌柏西利+氟维司群（Inavo/Pbo+Palbo+Fulv）一线辅助内分泌治疗完成期间/12个月内复发的 PIK3CA突变、HR+/HER2-局部晚期/转移性乳腺癌

讲者: Dejan Juric, MD | Medicine-Hematology and Medical Oncology, Massachusetts General Hospital Cancer Center
■摘要号：LBA1004

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer

随机II期试验SACI-IO HR+：戈沙妥珠单抗±帕博利珠单抗治疗转移性HR+/HER2-乳腺癌

讲者: Ana Christina Garrido-Castro, MD | Dana-Farber Cancer Institute
■摘要号：1005

Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202

EV-202研究：Enfortumab vedotin （EV）在三阴性乳腺癌（TNBC）和HR+/HER2-乳腺癌队列中的应用

讲者: Antonio Giordano, MD, PhD | Dana-Farber Cancer Institute
■摘要号：1006

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study

TROPION-Breast01研究中患者报告的结局：Dato-DXd vs化疗用于经治的不可切除或转移性HR+/HER2-乳腺癌

讲者: Sonia Pernas, MD, PhD | Institut Català d'Oncologia, IDIBELL, L’Hospitalet

■摘要号：1014

Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2

意大利多中心、真实世界、PALMARES-2研究的结果在HR+/HER2- aBC患者中比较哌柏西利、瑞波西利或阿贝西利一线治疗的抗肿瘤疗效。

讲者: Claudio Vernieri, MD, PhD, PhD (c) | Fondazione IRCCS INT
■摘要号：1015

H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC)
H3B-6545在局部晚期/转移性ER+/HER2-女性乳腺癌患者中的应用

讲者: Erika P. Hamilton, MD | Sarah Cannon Research Institute

■摘要号：1017

Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer.

ER+/HER2-转移性乳腺癌中的种族基因组特征及靶向治疗应用差异

讲者: Emily L Podany, MD | Washington University in St. Louis

■摘要号：511

Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline

MammaPrint指数与接受含蒽环类/不含蒽环类药物化疗的HR+/HER2-早期乳腺癌患者的3年结局的相关性

讲者: Joyce O'Shaughnessy, MD | Baylor University Medical Center, Texas Oncology, The US Oncology Network
■摘要号：512

Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial
NATALEE研究：淋巴结阴性HR+/HER2-早期乳腺癌患者的基线特征和疗效终点

讲者: Denise A. Yardley, MD | Sarah Cannon Research Institute

其他：聚焦基因组学与肿瘤微环境

■摘要号：LBA509

Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial

I-SPY2.2研究结果：datopotamab deruxtecan（Dato）新辅助治疗后的病理学完全缓解 （pCR）率

讲者: Jane Lowe Meisel, MD | Winship Canter Institute of Emory University

■摘要号：513

The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer

豁免辅助内分泌治疗对ER低表达（1-10%）早期乳腺癌的影响

讲者: Grace Mei Yee Choong, MD | Mayo Clinic
■摘要号：514

Oncologic outcome of response-guided axillary treatment in patients with cN1 breast cancer after primary systemic therapy.
基于初次全身治疗后cN1乳腺癌患者反应导向腋窝治疗的肿瘤学结局

讲者: Annemiek van Hemert, MD | Antoni van Leeuwenhoek / Netherlands Cancer Institute
■摘要号：515

Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial
RxPONDER研究：按人种和种族列出的复发评分基因轴评分结局

讲者: Yara Abdou, MD | The University of North Carolina at Chapel Hill
■摘要号：516


Non-basal subtype defined by FOXC1 expression as an independent predictor of capecitabine efficacy in the triple negative breast cancer GEICAM/2003-11_CIBOMA/2004-01 trial
GEICAM/2003-11_CIBOMA/2004-01研究：以OXC1表达定义的非基底亚型作为卡培他滨治疗TNBC的疗效独立预测因子

讲者: Federico Gustavo Rojo Todo, MD, PhD | Hospital Universitario Fundación Jiménez Díaz; CIBERONC-ISCCIII; GEICAM Spanish Breast Cancer Group
■摘要号：517
Associations of predictive biomarkers, MHC-I and MHC-II, with clinical and molecular features in a diverse breast cancer cohort
在不同的乳腺癌队列中，预测性生物标志物MHC-I和MHC-II与临床分子特征的相关性

讲者: Sonya A. Reid, MD, MPH | Vanderbilt University Medical Center

■摘要号：1016

Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial
SONIA研究：内分泌治疗±CDK4/6抑制剂治疗的HR+晚期乳腺癌患者的认知功能

讲者: Maryse Luijendijk, MSc | Psychosocial Research and Epidemiology, Netherlands Cancer Institute
■摘要号：1018

Genomic and tumor microenvironment dynamics of brain metastases in breast cancer.

乳腺癌脑转移的基因组和肿瘤微环境动态

讲者: DHARMINI MANOGNA, MD | Tulane Medical University
■摘要号：1019

Clinical utility of molecular imaging in newly diagnosed metastatic breast cancer.

分子影像在新诊断的转移性乳腺癌中的临床应用

讲者: Carolina Pia Schroder, MD, PhD | Department of Medical Oncology, Netherlands Cancer Institute
■摘要号：1021

TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2

II期研究TBCRC 048扩展队列：奥拉帕利单药治疗携带gPALB2突变或体细胞BRCA1/2突变的转移性乳腺癌

讲者: Nadine M. Tung, MD, FASCO | Beth Israel Deaconess Medical Center
■摘要号：1022
Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.

BRIA-IMT（一种同种异体全细胞免疫治疗）治疗晚期/转移性乳腺癌的结局

讲者: Carmen Julia Calfa, MD | Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine

精彩资讯等你来

责任编辑：Sheep

*医学界力求其发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。